456 related articles for article (PubMed ID: 27881129)
1. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
Liu X; Men P; Wang Y; Zhai S; Liu G
Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
3. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
[TBL] [Abstract][Full Text] [Related]
5. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
7. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
Kostev K; Schokker E; Jacob L
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
Göke R; Eschenbach P; Dütting ED
Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
11. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
[TBL] [Abstract][Full Text] [Related]
12. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
[TBL] [Abstract][Full Text] [Related]
14. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
[TBL] [Abstract][Full Text] [Related]
17. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
Acta Diabetol; 2020 Jun; 57(6):689-696. PubMed ID: 31955260
[TBL] [Abstract][Full Text] [Related]
18. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH; Chang YC; Lin JW; Caffrey JL; Wu LC; Lai MS; Chuang LM
Int J Cardiol; 2016 Oct; 220():14-20. PubMed ID: 27389437
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes.
Oh TJ; Jung HS; Bae JH; Kim YG; Park KS; Cho YM; Park KS; Kim SY
J Korean Med Sci; 2013 Jun; 28(6):881-7. PubMed ID: 23772153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
